The Compliance of Varenicline With Short-massage

Smoking Clinical Trial

— CV-SM  

Official title:

The Compliance of Varenicline Usage and the Smoking Abstinence Rate Via Mobile Phone Text Messaging Combine With Varenicline: a Single-blind, Randomised Control Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01656083
• Other study ID #: SM2010CHINA
• Status: Recruiting
• Phase: N/A
• First received: July 31, 2012
• Last updated: August 1, 2012
• Start date: May 2010
• Est. completion date: December 2012

Study information

• Verified date: July 2012
• Source: China-Japan Friendship Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Research indicated that the relapse rate of smokers who attempted to give up smoking without drug and other assistance is up to 90-95% while the successful cessation rate may be improved a lot with assistance to quit smoking. There are two kinds of measures to help smokers quit smoking: one is psychological and behavioral intervention, including the advice to quit smoking provided by doctors during daily health service and smoking cessation hotline; another is provision of drug therapy. 2008 smoking cessation Guidance plays emphasis on the effectiveness of smoking cessation of Varenicline and also on role of doctor's behavioral intervention in smoking cessation as Class A of evidence-based rating; among which, doctor's consultation (three minutes) at minimum intensity is effective; high-intensity consultation (more than ten minutes) is more effective than that of low-intensity consultation; and return visit for more than four times will distinctively improve the smoking abstinence rate. It is unrealistic to apply high-intensity and high-frequency smoking cessation intervention on all smokers due to the busy clinical work of domestic doctors. Systematic and standardized short message intervention system may be helpful to improve abstinence rate. Meanwhile, it can reduce human labor and physical resources, and improve the frequency of follow-up visit to smokers. It is observed during the process of offering smoking cessation services to smokers that, it would be one of the very effective measures to provide timely and useful information to smokers at several critical phases of smoking cessation course (such as three weeks before smoking cessation, prevention of relapse, etc.). Doctors, however, are usually passive during this period and unable to provide assistance to smokers with initiative. As people are more and more aware of the harmfulness of smoking and more and more smokers are increasingly willing to give up smoking, it is necessary to create an instant active information distribution system, which provides immediate active smoking cessation short message support through universally used mobile phone short message service to achieve the purpose of helping them quit smoking.

Description:

Study design Random, parallel and control method is adopted.

1. Group division: random group division SM intervention group: SM intervention + varenicline Non-SM intervention group: varenicline

2. Method design Random, parallel and control method is adopted. In intervention group, SM is delivered by a standard designed SM platform system. The interactive SM supports are involved and trained professional staff will provide guidance regularly. The drug usage in two groups are the same.

Group Baseline 1st week 2nd week 3rd week 4th week 8th week 12th week 24th week Intervention Record Smoking history, consulting SM SM SM SM + Visit SM + Telephone visit SM + Visit SM + Visit Control Visit Telephone visit Visit Visit

Study population In this research, professional biostatistical staffs adopt SAS program to divide groups in the trial. The sample size is calculated based on drug compliance rate. Since lack of the data related to varenicline combined SM intervention, the similar trials in the past are taken as reference, but mostly based on the experiences of the investigator`s, the mean treatment time for patients using Varenicline is 4 weeks, the proportion of patients who use Varenicline for 4 weeks is about 40%; when combined SM intervention, it supposed to increase to 60% . When use 80% power and 0.05 significance for calculation, the sample size is 192, 96 for each group. Considering the drop rate is about 15%, 220 qualified subjects are included in random group division.

Treatment program

1. Treatment program The drug administered is varenicline. This drug has been recommended as the first-line smoking-cessation drug by American smoking-cessation guide in 2008. The abstinence rate is 3.1 times higher than that of placebo [3]-109, which is the highest rate among smoking-cessation drugs at present. This drug is manufactured by Pfizer Company and should be used strictly in light of the use instruction.

2. Intervention

1) Contents of psychological behavior intervention 2) SM intervention

Regular SM for smoking cessation

It is active SM delivery, no need of reply. SM is delivered at 9 o'clock on the assigned day to mobile phones of target people. The frequency of delivery is as follows:

Time Frequency

1 day before smoking cessation 1pcs/d The 1st week of smoking cessation 2pcs/d The 2nd week of smoking cessation 1pcs/d The 3rd to 4th weeks of smoking cessation 1pcs/d The 2nd to 6th months of smoking cessation 1pcs/w

Objectives Primary observation index 1) Drug compliance for 4 weeks: defined as the proportion of patients who use Varenicline for 4 weeks to all the patients in this group.

Secondary observe index

1. Drug compliance for 6, 8, 10 and 12 weeks: the proportion of patients using varenicline for 6, 8,10 and 12 weeks to all the patients;

2. Continuous abstinence(CA) rates: These rates are defined as the proportion of participants who met abstinence criteria for weeks 9 through 12 and reported no smoking or use of tobacco products at clinic or telephone visits, confirmed by exhaled carbon monoxide measurement of 10 ppm or less at clinic visits only.

3. Long-term abstinence rates: it is the rate at the follow-up of the 24th week and verified by exhaled CO test.

Safety The safety indexes include i. General items: blood pressure, heart rate, respiration ii. Blood and urine routine, liver and kidney functions iii. ECG iv. All of the recorded adverse events v. Severe adverse events: terminate trial immediately and deal with them in time.

Record and report of adverse event

1. Definition

1. Adverse event: any untoward medical conditions occurrence in a patient administered the drug.

2. Serious adverse event: below adverse events occurrence in drug use: death, life threatened, prolong hospitalization, disabled and teratogenic.

2. The relationship between adverse event and trial drug Data management

1. Filling-up Case Report

2. Data input

3. Data lock

4. Data management Statistical analysis SPSS 10.01 statistical software is adopted. Differences in treatment period between two groups were evaluated using Kaplan-Meier survival curves, with log-rank test, Cox proportional hazard models, Bilateral test is used in all of statistical test, P<0.05 is viewed to be statistical significant difference.

Parametric method is adopted for normality data and the data of homogeneity of variance, including mainly independent t test, paired t test, variance analysis, analysis of covariance, etc. For the data of non-normal distribution and uneven variance, non-parametric method is adopted, including Chi-square test, exact probability method, rank test, etc.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 220
• Est. completion date: December 2012
• Est. primary completion date: July 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Smoking over 10 years

2. Over 10 cigarettes each day

3. Age 18 to 70 years

4. Have strong motivation to quit smoking

5. Be suitable and willing to receive Varenicline treatment

6. Be able to receive SM and willing to receive relevant information

7. Sign the Informed Consent Form

Exclusion Criteria:

1. Serious abnormality of liver and kidney functions

2. Have serious skin allergy or mental diseases history, or any other disease not suitable for using Varenicline

3. Alcohol abuse or other drug abuse

4. Any concomitant illness or mental condition that could interfere with the study

5. Any conditions indicating study subjects uncooperative

6. Unable to receive or read SM

7. Any subject that Investigators think not to be suitable for enrollment.

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Smoking

Locations

Country	Name	City	State
Germany	MicroCO/SmokeCheck	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
yu hong xia

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Heckman CJ, Egleston BL, Hofmann MT. Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis. Tob Control. 2010 Oct;19(5):410-6. doi: 10.1136/tc.2009.033175. Epub 2010 Jul 30. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Drug compliance varenicline	Drug compliance for 4 weeks: defined as the proportion of patients who use Varenicline for 4 weeks to all the patients in this group.	4weeks	Yes
Secondary	Continuous abstinence(CA) rates	Drug compliance for 6, 8, 10 and 12 weeks: the proportion of patients using varenicline for 6, 8,10 and 12 weeks to all the patients; Continuous abstinence(CA) rates: These rates are defined as the proportion of participants who met abstinence criteria for weeks 9 through 12 and reported no smoking or use of tobacco products at clinic or telephone visits, confirmed by exhaled carbon monoxide measurement of 10 ppm or less at clinic visits only.; Long-term abstinence rates: it is the rate at the follow-up of the 24th week and verified by exhaled CO test.	24weeks	Yes